1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
Catenin Beta 1 (Beta Catenin or CTNNB1) pipeline Target constitutes close to 14 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The latest report Catenin Beta 1 - Pipeline Review, H2 2020, outlays comprehensive information on the Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Catenin Beta 1 (Beta Catenin or CTNNB1) - Catenin beta-1 or β-catenin is a protein that is encoded by the CTNNB1 gene. In the presence of Wnt ligand, CTNNB1 acts as a coactivator for transcription factors of the TCF/LEF family, leading to activate Wnt responsive genes. It is involved in the regulation of cell adhesion, CDK2/PTPN6/CTNNB1/CEACAM1 pathway of insulin internalization. It also acts as a negative regulator of centrosome cohesion. It blocks anoikis of malignant kidney and intestinal epithelial cells and promotes their anchorage-independent growth by down-regulating DAPK2. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 1, 6 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Non Malignant Disorders, Gastrointestinal and Respiratory which include indications Colorectal Cancer, Melanoma, Solid Tumor, Breast Cancer, Hepatocellular Carcinoma, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Anaplastic Thyroid Cancer, Benign Tumor, Blood Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Head And Neck Cancer, Hemangiomas, Hematological Tumor, Hepatic (Liver) Tumor, Idiopathic Pulmonary Fibrosis, Leukemia, Liver Cirrhosis, Lung Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
Furthermore, this report also reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Catenin Beta 1 (Beta Catenin or CTNNB1)
- The report reviews Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Catenin Beta 1 (Beta Catenin or CTNNB1) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Catenin Beta 1 (Beta Catenin or CTNNB1)Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Catenin Beta 1 (Beta Catenin or CTNNB1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionCatenin Beta 1 (Beta Catenin or CTNNB1) - OverviewCatenin Beta 1 (Beta Catenin or CTNNB1) - Drug Profiles
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Development
Catenin Beta 1 (Beta Catenin or CTNNB1) - Therapeutics Assessment
Catenin Beta 1 (Beta Catenin or CTNNB1) - Companies Involved in Therapeutics Development
Antisense RNAi Oligonucleotide to Inhibit Beta Catenin for Oncology - Drug Profile
BBI-801 - Drug Profile
exisulind - Drug Profile
Oligonucleotides for Hepatoblastoma - Drug Profile
PRI-724 - Drug Profile
PRP - Drug Profile
Small Molecule to Inhibit Beta Catenin and BCL9 for Colorectal Cancer - Drug Profile
Small Molecule to Inhibit Beta Catenin for Colorectal Cancer - Drug Profile
Small Molecules to Inhibit Beta Catenin for Oncology - Drug Profile
Synthetic Peptide for Oncology - Drug Profile
Synthetic Peptide to Inhibit CTNNB1 for Colorectal Cancer - Drug Profile
Synthetic Peptides to Inhibit Beta Catenin for Oncology - Drug Profile
Synthetic Peptides to Inhibit Beta Catenin for Solid Tumor and Blood Cancer - Drug Profile
WX-024 - Drug Profile
Catenin Beta 1 (Beta Catenin or CTNNB1) - Product Development Milestones
Appendix
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Aileron Therapeutics Inc
- Circle Pharma Inc
- Dicerna Pharmaceuticals Inc
- Fog Pharmaceuticals Inc
- iBeCa Therapeutics
- MD2 Biosciences Inc
- PRISM Pharma Co Ltd
- Propanc Biopharma Inc
- Sapience Therapeutics Inc
- Sumitomo Dainippon Pharma Oncology, Inc
- Venn Therapeutics LLC
- WntRx Pharmaceuticals Inc